List of Excipients in Branded Drug ALPRAZOLAM ODT C-IV

« Back to Dashboard

Generic Drugs Containing ALPRAZOLAM ODT C-IV

Company	Ingredient	NDC	Excipient
Direct_Rx	alprazolam odt c-iv	72189-637	ASPARTAME
Direct_Rx	alprazolam odt c-iv	72189-637	CROSPOVIDONE
Direct_Rx	alprazolam odt c-iv	72189-637	MAGNESIUM STEARATE

What are the Most Frequently-Used Excipients in ALPRAZOLAM ODT C-IV?

# Of NDCs	Excipient
1	ASPARTAME
1	CROSPOVIDONE
1	MAGNESIUM STEARATE

Alprazolam ODT C-IV Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: September 1, 2026

Alprazolam orally disintegrating tablets, classified as a U.S. Schedule IV controlled substance, offer formulation and commercial opportunities in rapid-dissolution delivery, differentiated packaging, pediatric and geriatric usability, and controlled-substance risk management. The core active ingredient is generic and broadly available. Commercial differentiation therefore depends on tablet performance, taste masking, moisture protection, supply reliability, and regulatory execution rather than molecule-level exclusivity.

What is alprazolam ODT C-IV?

Alprazolam ODT is an orally disintegrating tablet containing alprazolam, a benzodiazepine approved primarily for anxiety and panic disorder. ODT products are designed to disintegrate rapidly in the mouth without requiring the patient to swallow a conventional tablet with water.

The "C-IV" designation refers to Schedule IV under the U.S. Controlled Substances Act. The classification applies to alprazolam because of its abuse, dependence, and diversion risks. It affects prescribing, dispensing, inventory control, recordkeeping, packaging, and commercial positioning, but it does not prevent development of generic or reformulated ODT products.

Key product characteristics

Attribute	Alprazolam ODT
Active ingredient	Alprazolam
Drug class	Benzodiazepine
Dosage form	Orally disintegrating tablet
Common strengths	0.25 mg, 0.5 mg, 1 mg, and 2 mg
U.S. controlled-substance schedule	Schedule IV
Main therapeutic uses	Anxiety disorders and panic disorder
Regulatory pathway	ANDA for a therapeutically equivalent generic; 505(b)(2) for certain differentiated products
Primary commercial barrier	Demonstrating equivalent performance while controlling moisture sensitivity and taste
Primary abuse-related concern	Dependence, misuse, diversion, and co-use with opioids or other central nervous system depressants

The ODT route does not eliminate systemic exposure or benzodiazepine-related risks. It primarily changes administration convenience and tablet performance.

What excipients are used in alprazolam ODT products?

Alprazolam ODT formulations generally use a combination of water-soluble fillers, superdisintegrants, binders, sweeteners, flavors, lubricants, and taste-masking agents. The precise composition depends on the manufacturing platform and the regulatory reference product.

A representative excipient architecture is shown below.

Excipient category	Typical candidates	Commercial function
Bulking agent	Mannitol, lactose, sorbitol, microcrystalline cellulose	Provides tablet mass and mouthfeel
Superdisintegrant	Crospovidone, croscarmellose sodium, sodium starch glycolate	Promotes rapid tablet breakup
Binder	Povidone, copovidone, pregelatinized starch	Supports mechanical strength
Sweetener	Sucralose, aspartame, saccharin sodium, acesulfame potassium	Reduces alprazolam bitterness
Flavor	Mint, cherry, berry, citrus, or other pharmaceutical flavors	Improves acceptability
Lubricant	Magnesium stearate, sodium stearyl fumarate	Supports compression and ejection
Glidant	Colloidal silicon dioxide	Improves powder flow
Saliva-wetting aid	Poloxamer or other surfactant	Accelerates wetting and disintegration
Taste-masking system	Polymer coating, ion-exchange resin, cyclodextrin, lipid or particulate barrier	Limits drug release in the mouth
Moisture-control excipient	Low-hygroscopic filler or desiccant-compatible system	Supports stability and packaging performance

Mannitol is commercially attractive because it has a cooling mouthfeel, acceptable compressibility, and relatively favorable palatability. It can help create a more acceptable product than a lactose- or cellulose-dominant tablet. The formulation must still control hygroscopicity, friability, and compression behavior.

Crospovidone is commonly considered for rapid capillary-driven liquid uptake. Croscarmellose sodium can provide strong swelling and breakup performance, but excessive use may increase tablet expansion or affect mouthfeel. The optimal system depends on the target disintegration time, tablet hardness, and manufacturing process.

How should an alprazolam ODT excipient strategy be designed?

The formulation should be designed around five commercial targets: rapid wetting, low residual bitterness, sufficient mechanical strength, moisture stability, and consistent dose uniformity.

Rapid disintegration

A commercially credible ODT should disintegrate rapidly in a small volume of saliva while maintaining acceptable friability and handling strength. The developer should optimize:

• Tablet porosity
• Compression force
• Particle-size distribution
• Superdisintegrant concentration
• Binder level
• Lubrication time
• Granulation method
• Tablet thickness and geometry

Direct compression can reduce process complexity and cost. However, low-dose alprazolam creates a content-uniformity challenge because the drug load is small relative to total tablet mass. A robust premix, ordered mixing process, or granulation approach may be needed.

Taste masking

Alprazolam has a bitter taste. In an ODT, taste masking is more important than in a conventional tablet because the drug contacts the oral cavity before swallowing.

Potential approaches include:

1. Polymer-coated drug particles that delay dissolution in saliva.
2. Ion-exchange resin complexes that reduce immediate oral release.
3. Cyclodextrin complexation to reduce free drug concentration in the mouth.
4. Sweetener and flavor systems combined with rapid swallowing.
5. Multiparticulate or coated-granule incorporation into a rapidly disintegrating matrix.

Taste masking must not materially alter the pharmacokinetic profile. A coating that suppresses oral release but delays gastrointestinal release can create dissolution or bioequivalence problems.

Moisture control

ODTs are often moisture-sensitive because porosity, hygroscopic excipients, and low tablet hardness can reduce stability. Alprazolam ODT development should assess:

• Water activity
• Moisture uptake under accelerated conditions
• Tablet hardness after storage
• Disintegration after humidity exposure
• Assay and degradation products
• Blister seal integrity
• Desiccant compatibility
• In-use exposure after package opening

Unit-dose aluminum-aluminum blister packaging generally offers stronger moisture protection than high-density polyethylene bottles. It also supports controlled-substance dose accountability and portability. Bottles may have lower packaging cost but require stronger internal moisture control and patient-use stability data.

Low-dose content uniformity

A 0.25 mg strength is particularly sensitive to blend segregation and sampling error. Risk controls include:

• Narrow particle-size distribution
• Geometric dilution
• Controlled blending order
• In-process blend uniformity testing
• Validated hold times
• Low-shear transfer systems
• Dedicated equipment or validated cleaning procedures

A formulation that performs well at 1 mg may not transfer directly to 0.25 mg. Each strength requires dose-uniformity and dissolution evaluation.

What FDA regulatory pathway applies to alprazolam ODT?

An ANDA is the principal pathway for a generic alprazolam ODT that matches the reference listed drug in active ingredient, strength, dosage form, route, and labeling requirements, subject to permissible differences. The applicant must demonstrate pharmaceutical equivalence and bioequivalence under FDA requirements.

The reference product for U.S. alprazolam ODT has historically been Niravam, an orally disintegrating alprazolam product listed in FDA drug databases. The current reference-listed-drug and Orange Book status should be determined from the applicable FDA editions and listing records before filing or acquisition decisions. FDA approval status can change when products are discontinued, transferred, or relisted.

A 505(b)(2) application may be relevant where the product introduces a meaningful formulation or delivery difference that cannot be fully supported through an ANDA. Examples could include:

• A novel abuse-deterrent platform
• A materially different taste-masking technology
• A modified-release or dual-release design
• A different administration route
• A clinically supported pharmacokinetic difference
• A product with new dosing or safety information

A 505(b)(2) strategy is more expensive and carries greater clinical and regulatory risk than an ANDA. It may be commercially justified only if the formulation creates meaningful differentiation that generic substitution will not erase.

What patents protect alprazolam ODT products?

Alprazolam itself is long off-patent. The relevant intellectual-property analysis therefore focuses on formulation, manufacturing, packaging, and method-of-use claims.

Potential patent categories include:

Patent category	Possible claim scope	Commercial relevance
ODT composition	Specific excipient ratios, matrix structure, or drug form	May restrict a narrow formulation design
Taste masking	Coated particles, resin complexes, or flavor systems	Can create a formulation design-around issue
Manufacturing method	Granulation, compression, coating, or drying conditions	May affect process selection
Packaging	Moisture-barrier blister configuration or dose-dispensing system	Usually narrower than composition claims
Abuse deterrence	Physical, chemical, or extraction-resistant technology	May support differentiated positioning
Method of use	Specific dosing populations or administration instructions	May affect labeling and litigation risk

A patent covering a particular alprazolam ODT product does not automatically block all alprazolam ODT development. Claim construction, prosecution history, continuation status, terminal disclaimers, maintenance fees, and territorial coverage determine the practical risk.

For an ANDA applicant, the critical questions are whether the reference product has listed patents, whether any listed patents remain unexpired, and whether a Paragraph IV certification is required. FDA's Orange Book is the primary source for listed patents and exclusivity associated with approved small-molecule products.[1]

When does alprazolam ODT lose exclusivity?

The active ingredient and original alprazolam molecule patents no longer provide meaningful U.S. exclusivity. Any remaining protection is product-specific and may arise from later formulation patents, regulatory exclusivity, or non-listed intellectual property.

For alprazolam ODT:

• New chemical entity exclusivity is not relevant.
• Original alprazolam compound patents have expired.
• Standard generic entry is legally possible if FDA requirements are satisfied.
• Formulation patents must be assessed separately.
• Method-of-use patents may remain relevant only if listed or otherwise enforceable against the proposed labeling and conduct.
• Controlled-substance status does not create market exclusivity.

The commercial implication is that an ODT developer should assume competitive entry is possible unless a current, enforceable formulation or delivery patent has been identified.

Are Paragraph IV challenges likely for alprazolam ODT?

Paragraph IV risk depends on the presence of unexpired Orange Book-listed patents. If no relevant listed patents remain, an ANDA applicant may not need a Paragraph IV certification. If an active listed patent exists, the applicant may certify that the patent is invalid, unenforceable, or will not be infringed.

A Paragraph IV filing can create:

• Patent litigation within 45 days of notice
• A potential 30-month FDA approval stay
• Higher legal and regulatory costs
• Settlement negotiations
• Delayed launch or an agreed entry date

Because alprazolam ODT is a mature product class, the larger risk may be formulation patent disputes outside the obvious active-ingredient patent family. An applicant should screen U.S. patents and applications assigned to the reference-product sponsor, formulation developers, excipient-technology companies, and contract manufacturers.

What formulation opportunities exist for alprazolam ODT?

Improved taste masking

A low-bitter formulation with rapid gastrointestinal release could improve patient acceptance. The commercial value is strongest where existing products have poor palatability or where prescribers seek a more usable dosage form for patients who have difficulty swallowing.

Moisture-resistant unit-dose packaging

A differentiated blister system can reduce tablet degradation and improve portability. Unit-dose packaging also gives pharmacies and patients clearer dose accountability for a controlled substance.

Lower tablet mass

A smaller tablet can improve patient acceptance, but reducing mass may compromise content uniformity and mechanical strength. The target should balance mouthfeel with manufacturability.

Pediatric and geriatric usability

Alprazolam carries important safety and dependence concerns, so a pediatric strategy would face a high regulatory and clinical bar. Geriatric usability is a more commercially credible focus, particularly for patients with dysphagia or limited access to water. Labeling and risk management must remain consistent with approved indications and FDA requirements.

Abuse-deterrent features

Physical or chemical abuse deterrence could support a 505(b)(2) strategy, but the commercial case is difficult. Alprazolam ODT dissolves in the mouth by design, and a formulation optimized for rapid oral disintegration may not prevent misuse through other routes. Abuse-deterrent claims require evidence and FDA-compliant labeling; they cannot be inferred from the ODT dosage form alone.[2]

How strong is the patent estate for alprazolam ODT?

The molecule-level patent estate is weak because alprazolam is an established generic active ingredient. The formulation-level estate can be moderate only if it includes narrow but technically difficult claims covering:

• Specific coated alprazolam particles
• A defined excipient matrix
• A validated rapid-disintegration and dissolution profile
• Moisture-protective packaging integrated with the dosage form
• A clinically supported abuse-deterrent feature

Broad claims directed simply to "alprazolam in an orally disintegrating tablet" are vulnerable to prior-art and obviousness challenges. Stronger protection usually requires a defined composition, manufacturing condition, or performance limitation that is difficult to design around.

The most defensible commercial strategy is often a formulation portfolio rather than a single patent. That portfolio may include composition claims, process claims, packaging claims, and continuation applications directed to alternate excipient systems.

Which companies are competing in alprazolam ODT?

Competition includes the original branded or reference product sponsor, generic drug manufacturers, contract development and manufacturing organizations, and companies with ODT platforms.

The competitive landscape is shaped by:

• Availability of alprazolam API
• Access to low-dose content-uniformity manufacturing
• ODT compression or lyophilization capacity
• Taste-masking technology
• Controlled-substance compliance systems
• Pharmacy substitution and reimbursement
• Ability to maintain multiple strengths
• Packaging cost and supply continuity

A low-cost direct-compression product may compete effectively in commodity channels. A premium product requires a differentiator such as better palatability, smaller size, stronger packaging, or a clinically meaningful usability advantage.

What commercial opportunities exist for alprazolam ODT?

The strongest opportunities are incremental rather than molecule-led.

Opportunity	Value proposition	Main risk
Generic ANDA launch	Lower development cost and established demand	Price erosion and multiple generic entrants
Premium ODT	Better taste, portability, or disintegration	Limited reimbursement premium
Blister-packaged product	Moisture protection and controlled dispensing	Higher packaging cost
505(b)(2) product	Differentiated delivery or abuse-deterrent platform	Clinical and regulatory burden
Regional licensing	Local manufacturing or distribution access	Controlled-substance compliance
Contract manufacturing	Use of existing ODT capacity	Capacity, quality, and supply-chain dependence
Hospital and institutional supply	Standardized unit-dose packaging	Formulary and purchasing pressure

Revenue exposure is tied to the broader alprazolam market rather than ODT alone. Conventional tablets remain the dominant dosage form. An ODT developer should therefore model substitution rates, payer treatment, pharmacy stocking, and price erosion separately from total alprazolam prescription volume.

What manufacturing and IP barriers affect market entry?

The main manufacturing barriers are low-dose uniformity, moisture sensitivity, tablet friability, taste masking, and controlled-substance accountability. The main legal barriers are formulation patents, packaging claims, method-of-use patents, trade secrets, and potential Paragraph IV litigation.

A practical development sequence is:

1. Select a direct-compression or granulation platform.
2. Establish alprazolam content-uniformity controls.
3. Screen mannitol and superdisintegrant systems.
4. Select a taste-masking approach.
5. Compare bottle and unit-dose blister stability.
6. Confirm dissolution and bioequivalence strategy.
7. Conduct Orange Book and patent-family review.
8. Evaluate ANDA versus 505(b)(2) economics.
9. Build Schedule IV controls into manufacturing and distribution.
10. Prepare a multi-strength launch plan.

Geographic coverage is usually strongest in the United States, Canada, Europe, and selected emerging markets. Each jurisdiction applies different rules to controlled substances, generic substitution, data exclusivity, trademarks, and formulation patents. U.S. FDA approval does not establish marketing authorization elsewhere.

How does alprazolam ODT compare with conventional alprazolam tablets?

Factor	Alprazolam ODT	Conventional tablet
Water required	No	Usually yes
Oral disintegration	Rapid	Not designed for rapid oral breakup
Taste exposure	High	Lower
Moisture sensitivity	Often higher	Usually lower
Packaging need	Strong moisture protection often useful	Bottle or blister options
Manufacturing complexity	Higher	Lower
Generic price pressure	High	Very high
Differentiation potential	Moderate	Low
Abuse liability	Remains Schedule IV	Remains Schedule IV

ODT products can win on administration convenience, but they generally cannot command a durable premium without a clear patient, caregiver, payer, or institutional benefit.

Key Takeaways

• Alprazolam ODT is a mature generic opportunity with limited molecule-level patent protection.
• Excipient strategy should prioritize taste masking, rapid wetting, low-dose uniformity, mechanical strength, and moisture stability.
• Mannitol-based direct-compression systems are commercially attractive but require careful optimization of disintegrant, binder, lubricant, and flavor levels.
• Unit-dose moisture-barrier blister packaging can provide both product-stability and controlled-substance handling benefits.
• An ANDA is the most direct pathway for a conventional generic alprazolam ODT.
• A 505(b)(2) strategy requires meaningful formulation or delivery differentiation and a stronger evidence package.
• Paragraph IV risk depends on current Orange Book-listed patents, not on alprazolam's historical compound patents.
• The strongest patent opportunities are narrow formulation, process, packaging, and abuse-deterrent claims.
• Commercial returns will depend on substitution, reimbursement, manufacturing cost, and speed to market.
• Pediatric positioning is commercially and regulatorily difficult because of alprazolam's dependence and safety profile; geriatric usability and dysphagia-focused positioning are more practical development themes.

FAQs About Alprazolam ODT C-IV

Is alprazolam ODT a controlled substance?

Yes. Alprazolam ODT is a Schedule IV controlled substance in the United States. The ODT format does not change alprazolam's controlled-substance classification.

Can a company launch generic alprazolam ODT without a new clinical trial?

An ANDA may avoid a full efficacy trial if the applicant demonstrates pharmaceutical equivalence and bioequivalence to the applicable reference listed drug. A materially different product may require a 505(b)(2) application and additional clinical or pharmacokinetic evidence.

Does alprazolam ODT have an abuse-deterrent label?

The ODT dosage form alone does not establish abuse-deterrent status. Abuse-deterrent labeling requires an FDA-supported formulation and evidence package under applicable FDA guidance.

Which packaging is preferable for alprazolam ODT stability?

Unit-dose aluminum-based blister packaging generally offers strong moisture protection and dose accountability. Bottles may reduce packaging cost but require adequate moisture control and in-use stability support.

Can a new flavor create patent protection for alprazolam ODT?

A flavor alone is unlikely to create strong exclusivity. Patent value is more likely when the flavor is part of a defined taste-masking composition, coating system, manufacturing process, or demonstrated performance profile.

References

1. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files

2. U.S. Food and Drug Administration. (2017). General principles for evaluating abuse-deterrent formulations of opioid analgesic drugs: Guidance for industry. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/general-principles-evaluating-abuse-deterrent-formulations-opioid-analgesic-drugs

3. U.S. Food and Drug Administration. (2008). Guidance for industry: Orally disintegrating tablets. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/orally-disintegrating-tablets

4. U.S. Food and Drug Administration. (2024). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

5. U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/